Richard L. Schlenker
Thank you, Catherine, and good afternoon, everyone. Let me start by saying all comparisons will be on a year-over-year basis unless otherwise noted. For the second quarter of 2025, total revenues increased 1% to $142 million, and revenues before reimbursements or net revenues, as I will refer to them from here on, were approximately flat at $132.9 million as compared to the same period of 2024. Net income for the second quarter decreased to $26.6 million or $0.52 per diluted share as compared to $29.2 million or $0.57 per diluted share in the prior year period. During the quarter, the tax impact associated with share-based awards was immaterial compared to a tax benefit of $700,000 or $0.01 per share in the second quarter of 2024. Inclusive of the tax impact for share-based awards, Exponent's consolidated tax rate was 27.9% in the second quarter of 2025 as compared to 26.3% for the same period in 2024. EBITDA for the quarter decreased 7% to $37 million, producing a margin of 27.8% of net revenues as compared to $39.9 million or 30.2% of net revenues in the same period in 2024. This year-over-year decrease in margins was primarily due to the decrease in utilization, an increase in the other operating expenses largely associated with the Phoenix land lease renewal during June of 2024 and a decrease in miscellaneous income due to the loss of a tenant at our Menlo Park facility. Billable hours in the second quarter were approximately $359,000, a decrease of 6% year-over-year. The average number of technical full-time equivalent employees in the second quarter was 958, down 2% as compared to 1 year ago. Utilization in the second quarter was 72.1%, down from 75.1% in the same period of 2024. The decrease was due, in part, to the inclusion of the July 4 holiday in the second quarter, which resulted in 1 less day of billable activity compared to fiscal 2024 when the holiday occurred in the third quarter. For the quarter, our utilized -- our realized rate increase was approximately 5% as compared to the same period a year ago. This is a result of our premium position in the marketplace, unparalleled talent and differentiated interdisciplinary expertise. In the quarter, compensation expense after adjusting for gains and losses in deferred compensation increased 2%. Included in total compensation expense is a deferred compensation gain of $17 million as compared to a gain of $875,000 in the same period of 2024. As a reminder, gains and losses in deferred compensation are offset in miscellaneous income and have no impact on the bottom line. Stock-based compensation expense in the quarter was $2.1 million as compared to $2.3 million in the prior year period. Other operating expenses in the quarter were up 8% to $12.1 million, driven primarily by the increased noncash expense associated with our Phoenix lease extension. Included in other operating expenses is a depreciation and amortization expense of $2.5 million for the second quarter. G&A expenses increased 2% to $6.1 million for the quarter. Interest income increased to $2.3 million for the quarter, driven by an increase in cash and cash equivalents. Miscellaneous income, excluding the deferred compensation gain, was approximately $331,000 for the quarter. During the quarter, capital expenditures were $2.3 million. We distributed $15.2 million to shareholders through dividend payments and repurchased $27.7 million of common stock at an average price of $75.66. Turning to our segments. Exponent's engineering and other scientific segment represented 85% of net revenues in the second quarter. Net revenues in this segment increased 1%, driven by demand for Exponent's dispute-related services in the construction, automotive and medical device sectors. Exponent's environmental and health segment represented 15% of net revenues in the second quarter. Net revenues in this segment decreased 4% due to a lower level of activity for proactive projects in the life sciences sector and our chemical regulation services. Turning to our outlook. For the third quarter 2025, as compared to 1 year prior, we expect revenues before reimbursements to be up in the middle single digits and EBITDA to be 26.75% to 27.75% of revenue before reimbursements. For fiscal year 2025, we are maintaining our full year guidance. We expect revenues before reimbursements to grow in the low single digits and EBITDA to be 26.5% to 27% of revenues before reimbursements. As a reminder, the 13-week fourth quarter of this year will be compared to a 14-week fourth quarter in fiscal 2024. As a result, we will experience a year-over-year revenue headwind of approximately 6% due to the decrease in workdays in the fourth quarter of 2025. We expect year-over-year technical full-time equivalent employees to be up approximately 1% to 2% for the third quarter. We are pleased to be returning to headcount growth as we started the year with a 5% to 6% deficit in FTEs. This growth in headcount is a result of our recruiting activities and a normalized turnover rate. As such, we are now -- we are starting the third quarter with headcount up approximately 1% as compared to the beginning of the second quarter of 2025. Based on our acceptances and these trends, we expect at year-end that headcount will be approximately 4% higher than at the start of the year. We expect utilization in the third quarter to be 72% to 73% as compared to 73% in the same quarter last year. For the full year, we expect utilization to be approximately 72% as compared to 73% in 2024. We expect the year-over-year realized rate increase to be 4% to 5% for the third quarter and the full year. For the third quarter, we expect stock-based compensation to be $5.3 million to $5.5 million. For the full year, we expect stock-based compensation to be $23.5 million to $24 million. For the third quarter, we expect other operating expenses to be $12.5 million to $13 million. For the full year, we expect them to be $49.5 million to $50.5 million. As noted in prior quarters, the year-over-year increase in the full year other operating expenses is largely driven by the extension of our Phoenix lease. For the third quarter, we expect G&A expenses to be $7.5 million to $8 million. For the full year, we expect them to be $24.8 million to $25.5 million. The increase in G&A for the third quarter and full year is primarily due to an expense of approximately $2 million for a firm-wide managers meeting in September of 2025. The meeting is an important investment in people development that bring together our multidisciplinary teams, develop our key talent and foster the next generation of leaders and business generators. We expect interest income to be $2 million to $2.2 million per quarter for the remainder of 2025. In addition, we anticipate miscellaneous income to be approximately $200,000 per quarter for the remainder of the year. We continue to work to replace the rental income we lost in our Menlo Park facility. For the remainder of 2025, we do not anticipate any additional tax benefit associated with share-based awards. For the third quarter of 2025, we expect our tax rate to be approximately 28% as compared to 27.5% in the same quarter 1 year ago. For the full year 2025, the tax rate is expected to be 28.5% as compared to 26% in 2024. The increase in the tax rate is due to a decrease in the tax benefit from share-based awards. Capital expenditures for the full year 2025 are expected to be $10 million to $12 million. In closing, we are excited about our prospects for future growth. I will now turn the call back to Catherine for closing remarks.